| DOC |
Report |
Q2 2026 adjusted FFO per share |
BEAT |
pred ~$0.45 vs. cons $0.44 |
MEDIUM |
| DOC |
Report |
Q2 2026 lab total occupancy |
IN-LINE |
pred ~77.4% vs. cons 77.5% |
MEDIUM |
| DOC |
Report |
Q2 2026 total same-store adjusted NOI growth |
BEAT |
pred ~0.9% vs. cons 0.7% |
LOW |
| DOC |
Guide |
Adjusted FFO per share guidance |
UNCHANGED |
guide ~$1.75 midpoint ($1.73–$1.77) vs. cons $1.75 (FY2026) |
MEDIUM |
| DOC |
Guide |
Total same-store adjusted NOI growth guidance |
LOWER |
guide ~0.0% midpoint (-1.0% to 1.0%) vs. cons 0.3% (FY2026) |
MEDIUM |
| DOC |
Guide |
Lab total occupancy guidance |
LOWER |
guide ~78.0% or better vs. cons 78.2% (year-end 2026) |
MEDIUM |
| DOC |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| DOC |
Return |
5-day cumulative residual |
+0.7% (FADE) |
Day-1 residual of +1.8% fades to a +0.7% five-day residual: a modest Q2 FFO beat and stable lab trajectory support the initial reaction, but a ~$1.75 FY2026 guidance midpoint versus ~$1.75 consensus implies roughly $0.425 per quarter in 2H after two ~$0.45 quarters, limiting upward revisions as refinancing and asset-recycling dilution enter the out-period math. |
MEDIUM |